Please note that this meeting will take place as an in-person event in Toronto and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program in progress.

Sunday, October 1, 2023

Welcome and Opening Keynote Lecture

Monday, October 2

Plenary Session 1: T-cell Biology
Plenary Session 2: Macrophages and Myeloid Cells
Plenary Session 3: Inhibitory Cells

Tuesday, october 3

Plenary Session 4: Lymphocyte Subsets Impacting Anti-tumor Immunity
Plenary Session 5: Metabolic Modulation of Anti-tumor Immunity
Plenary Session 6: TCR-targeted Immunotherapies

Wednesday, octoBer 4

Plenary Session 7: Spatial Profiling
Plenary Session 8: Synthetic Biology and Immune Cell Engineering
Plenary Session 9: Engineered Cytokines

Sunday, October 1, 2023

Registration
3-8 p.m.

Welcome and oPENInG Keynote Lecture
6:30-7:30 P.M.

Welcome and Introduction of Keynote Speaker
Philip D. Greenburg, Fred Hutchinson Cancer Research Center, Seattle, Washington

Keynote Lecture
Chasing T Cell Exhaustion
Crystal L. Mackall, Stanford University School of Medicine, Stanford, California

Opening reception
7:30-9:30 p.m.

Monday, october 2

Continental breakfast
7-8 a.m.

Plenary Session 1: T-cell Biology
Session Chair: Andrea Schietinger, Memorial Sloan Kettering Cancer center, New York, New York
8-10:05 A.M.

Critical role for Batf3-lineage dendritic cells within the tumor microenvironment
Thomas F. Gajewski, University of Chicago, Chicago, Illinois

Title to be announced
Andrea Schietinger

Elucidating mechanisms of immunotherapy response and resistance in pancreatic cancer
Ingunn Stromnes, University of Minnesota Medical School, Minneapolis, Minnesota

Regulation of exhausted CD8⁺ T cell differentiation by IKZF transcription factors*
Sinead M. Reading, Peter MacCallum Cancer Centre, Melbourne, Australia

Panel Discussion

bREAK
10:05-10:25 A.M.

pLENARY sESSION 2: MACROPHAGES AND MYELOID CELLS
Session Chair: Jennifer L. Guerriero, Brigham and Women’s Hospital, Boston, MASSACHUSETTS
10:25 A.M.-12:30 p.m.

Title to be announced
Matthew Krummel, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Title to be announced
Aaron M. Newman, Stanford University, Stanford, California

Unraveling the complexities of tumor associated macrophages for anti-cancer therapy of breast cancer
Jennifer L. Guerriero

Lyn kinase regulates myeloid-cell responses to mammary tumors*
Joseph T. Greene, Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota

Panel Discussion

Lunch on Own/Free Time
12:30-2:30 P.M.

pLENARY sESSION 3: Inhibitory Cells
Session Chair: PAMELA S. OHASHI, UHN PRINCESS MARGARET CANCER CENTRE, TORONTO, ONTARIO, CANADA
2:30-4:35 P.M.

Title to be announced
Robert D. Schreiber, Washington University School of Medicine in St. Louis, Missouri

Title to be announced
Pamela S. Ohashi

PMN-MDSC in regulation of immune suppressive microenvironment in cancer
Dmitry Gabrilovich, AstraZeneca, Philadelphia, Pennsylvania

Hypoxia promotes inflammatory fibroblast formation in pancreatic cancer*
Ashley M. Mello, University of Michigan, Ann Arbor, Michigan

Panel Discussion

pOSTER SESSION A/RECEPTION
4:45-7:00 P.M.

Abstracts to be presented at the conference

eVENING OFF/DINNER ON OWN
7:00 P.M.

tUESDAY, OCTOBER 3

Continental Breakfast
7-8 A.M.

Plenary Session 4: Lymphocyte Subsets Impacting Anti-tumor Immunity
Session Chair: Dario a. a. vignali, University of pittsburgh, Pittsburgh, pennsylvania
8-10:05 A.M.

Interferon modification of T cell function and response to immunotherapy
David G. Brooks, University of Toronto, Toronto, Ontario, Canada

Title to be announced
Tak W. Mak, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada

LAG-3: The third checkpoint inhibitor & its synergistic interactions with PD1
Dario A. A. Vignali

Temporal single cell profiling identifies B-cell specific checkpoint molecules that regulate anti-tumor immunity*
Lloyd Bod, Massachusetts General Hospital, Boston, Massachusetts

Panel Discussion

Break
10:05-10:25 A.M.

Plenary Session 5: Metabolic Modulation of Anti-Tumor Immunity
Session Chair: Greg M. delgoffe, UPMC Hillman cancer center, pittsburgh, pennsylvania
10:25 a.m.-12:30 p.m.

Title to be announced
Greg M. Delgoffe

Obesity and immunometabolism in cancer immunotherapy
Jeffrey C. Rathmell, Vanderbilt University Medical Center, Nashville, Tennessee

Title to be announced
Ping-Chih Ho, University of Lausanne, Lausanne, Switzerland

Dgat1 camouflages sexual dimorphism in anti-tumor CD8+ T cell immunity*
Alaa Madi, German Cancer Research Center, Heidelberg, Germany

Panel Discussion

lunch on own/free time
12:30-2:30 p.m.

plenary session 6: tcr-targeted immunotherapies
Session Chair: Catherine j. Wu, dana-farber cancer institute, boston, massachusetts
2:30-4:35 p.m.

Title to be announced
Catherine J. Wu

Cancer Neoantigens: From Discovery to the Clinic
Nina Bhardwaj, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York

Title to be announced
Paul G. Thomas, St. Jude Children’s Research Hospital, Memphis, Tennessee

Hallmarks of CD8 T cell dysfunction are established within hours of tumor antigen encounter prior to cell division*
Mary Philip, Vanderbilt University Medical Center, Nashville, Tennessee

Panel Discussion

Poster session b/reception
4:45-7:00 p.m.

Posters to be presented at the conference

Evening Off/Dinner on own
7:00 P.M.

Wednesday, october 4

Continental Breakfast
7-8 a.m.

plenary session 7: spatial profiling
sESSION cHAIR: R. Michael Angelo, Stanford University, Palo Alto, California
8-9:50 a.m.

Identifying regulators of tumor immunity by spatial functional genomics
Brian D. Brown, Icahn School of Medicine at Mount Sinai, New York, New York

A spatial framework for predicting outcome in breast cancer
R. Michael Angelo

Recirculating tumor-specific T cell responses as biomarkers for virally driven cancers
Evan Newell, Fred Hutchinson Cancer Research Center, Seattle, Washington

Panel Discussion

Break
9:50-10:05 a.m.

Plenary session 8: synthetic biology and immune cell engineering
Session Chair: Phillip D. Greenberg, Fred Hutchinson Cancer Research Center, SEattle, Washington
10:05-11:55 a.m.

Title to be announced
Carl H. June, Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania

Title to be announced
Philip D. Greenberg

Title to be announced
Michael Sadelain, Memorial Sloan Kettering Cancer Center, New York, New York

Panel Discussion

Break
11:55 a.m.-12:10 p.m.

plenary session 9: engineered cytokines
Session Chair: Mario Sznol, Yale University, New Haven, Connecticut
12:10-2 p.m.

Title to be announced
Pablo Umana, Roche, Schlieren, Switzerland

Title to be announced
Ivana Djuretic, Asher Biotherapeutics, Inc., South San Francisco, California

Title to be announced
Mario Sznol

closing comments and departure
2 p.m.

Mario Sznol, Yale University, New Haven, Connecticut

* Short talk from proffered paper